Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1/2 Mutation”

126 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 126 results

Not applicableUnknownNCT05391763
What this trial is testing

Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia?

Who this might be right for
BRCA1/2 MutationBilateral Prophylactic MastectomySeroma+1 more
Erasmus Medical Center 21
Not applicableStudy completedNCT00579007
What this trial is testing

Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations

Who this might be right for
Breast CancerOvarian Cancer
Memorial Sloan Kettering Cancer Center 224
Not applicableLooking for participantsNCT02478892
What this trial is testing

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

Who this might be right for
Pancreatic Cancer
Abramson Cancer Center at Penn Medicine 200
Testing effectiveness (Phase 2)Study completedNCT02789332
What this trial is testing

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more
GBG Forschungs GmbH 107
Testing effectiveness (Phase 2)Active Not RecruitingNCT03480776
What this trial is testing

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Who this might be right for
Ovarian Cancer Prevention
Canadian Cancer Trials Group 117
Not applicableStudy completedNCT00858078
What this trial is testing

A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women

Who this might be right for
BRCA1 GeneBRCA2 Gene
National Cancer Institute (NCI) 76
Early research (Phase 1)Ended earlyNCT02561832
What this trial is testing

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT03344965
What this trial is testing

Olaparib In Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerInvasive Breast CancerSomatic Mutation Breast Cancer (BRCA1)+7 more
Beth Israel Deaconess Medical Center 114
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Not applicableActive Not RecruitingNCT04499534
What this trial is testing

BRCA1/2 Flu Vaccine

Who this might be right for
BRCA1 MutationBRCA2 Mutation
Abramson Cancer Center at Penn Medicine 50
Testing effectiveness (Phase 2)Ended earlyNCT02034916
What this trial is testing

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 84
Not applicableEnded earlyNCT01103128
What this trial is testing

Validation of a Mouse Model of Pancreatic Carcinogenesis

Who this might be right for
Pancreatic Cancer
Columbia University 450
Early research (Phase 1)Study completedNCT02418624
What this trial is testing

Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer

Who this might be right for
Breast CancerOvarian CancerAdvanced Cancer
The Netherlands Cancer Institute 25
Not applicableLooking for participantsNCT02516540
What this trial is testing

Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers

Who this might be right for
Hereditary Breast and Ovarian Cancer
Technical University of Munich 600
Testing effectiveness (Phase 2)WithdrawnNCT05482074
What this trial is testing

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Who this might be right for
Recurrent Metastatic MelanomaCutaneous MelanomaMucosal Melanoma+1 more
Dana-Farber Cancer Institute
Early research (Phase 1)WithdrawnNCT05807126
What this trial is testing

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT04493060
What this trial is testing

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
Mayo Clinic 22
Not applicableLooking for participantsNCT07197723
What this trial is testing

Study of How People Make Decisions About Prostate Cancer Risk

Who this might be right for
BRCA1/2Geneitic Testing
Memorial Sloan Kettering Cancer Center 150
Very early researchEnded earlyNCT03382574
What this trial is testing

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Who this might be right for
Ovarian Carcinoma
National Cancer Institute (NCI) 2
Not applicableLooking for participantsNCT06817694
What this trial is testing

Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene

Who this might be right for
Breast Cancer Susceptibility Gene (BRCA1) MutationBRCA2 MutationFear of Cancer Recurrence
CHU de Quebec-Universite Laval 250
Load More Results